Immunosuppressive treatment for autoimmune blistering diseases does not impair production of neutralizing antibodies after "booster" dose of COVID-19 vaccine.Int J Dermatol. 2023 Jul; 62(7):847-849.IJ
Abstract
Since vaccines against COVID-19 are available, it has been debated if immunosuppressed patients with autoimmune blistering diseases (AIBDs) should be advised to interrupt the immunosuppressive therapy before receiving the vaccine, with consequent risk to experience a flare of disease. In the present study, we measured the neutralizing antibodies production after anti-SARS-CoV-2 vaccination in patients with AIBDs on immunosuppressive treatment, compared to healthy controls. Our results give strength to the hypothesis that these patients do not need to discontinue their therapy to produce effective levels of neutralizing antibodies, in other words to achieve successful protection.
Links
MeSH
Pub Type(s)
News
Language
eng
PubMed ID
37185976
Citation
Russo, Roberto, et al. "Immunosuppressive Treatment for Autoimmune Blistering Diseases Does Not Impair Production of Neutralizing Antibodies After "booster" Dose of COVID-19 Vaccine." International Journal of Dermatology, vol. 62, no. 7, 2023, pp. 847-849.
Russo R, Capurro N, Cozzani E, et al. Immunosuppressive treatment for autoimmune blistering diseases does not impair production of neutralizing antibodies after "booster" dose of COVID-19 vaccine. Int J Dermatol. 2023;62(7):847-849.
Russo, R., Capurro, N., Cozzani, E., Gasparini, G., Canepa, P., & Parodi, A. (2023). Immunosuppressive treatment for autoimmune blistering diseases does not impair production of neutralizing antibodies after "booster" dose of COVID-19 vaccine. International Journal of Dermatology, 62(7), 847-849. https://doi.org/10.1111/ijd.16695
Russo R, et al. Immunosuppressive Treatment for Autoimmune Blistering Diseases Does Not Impair Production of Neutralizing Antibodies After "booster" Dose of COVID-19 Vaccine. Int J Dermatol. 2023;62(7):847-849. PubMed PMID: 37185976.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Immunosuppressive treatment for autoimmune blistering diseases does not impair production of neutralizing antibodies after "booster" dose of COVID-19 vaccine.
AU - Russo,Roberto,
AU - Capurro,Niccolὸ,
AU - Cozzani,Emanuele,
AU - Gasparini,Giulia,
AU - Canepa,Paola,
AU - Parodi,Aurora,
Y1 - 2023/04/26/
PY - 2023/3/28/revised
PY - 2023/2/14/received
PY - 2023/4/4/accepted
PY - 2023/6/14/medline
PY - 2023/5/15/pubmed
PY - 2023/5/15/entrez
SP - 847
EP - 849
JF - International journal of dermatology
JO - Int J Dermatol
VL - 62
IS - 7
N2 - Since vaccines against COVID-19 are available, it has been debated if immunosuppressed patients with autoimmune blistering diseases (AIBDs) should be advised to interrupt the immunosuppressive therapy before receiving the vaccine, with consequent risk to experience a flare of disease. In the present study, we measured the neutralizing antibodies production after anti-SARS-CoV-2 vaccination in patients with AIBDs on immunosuppressive treatment, compared to healthy controls. Our results give strength to the hypothesis that these patients do not need to discontinue their therapy to produce effective levels of neutralizing antibodies, in other words to achieve successful protection.
SN - 1365-4632
UR - https://www.unboundmedicine.com/medline/citation/37185976/Immunosuppressive_treatment_for_autoimmune_blistering_diseases_does_not_impair_production_of_neutralizing_antibodies_after_"booster"_dose_of_COVID-19_vaccine.
DB - PRIME
DP - Unbound Medicine
ER -
Try the Free App:
